NeoGenomics, Inc.: NeoGenomics Reports Third Quarter 2022 Results

Third Quarter Revenue Increased 6% to $129 MillionFORT MYERS, FL / ACCESSWIRE / November 8, 2022 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of cancer-focused genetics testing

Related Keywords

Fort Myers ,Florida ,United States ,Georgia ,Tampa ,North Carolina ,Texas ,Research Triangle Park ,Atlanta ,China ,California ,Tennessee ,Singapore ,Houston ,Aliso Viejo ,Switzerland ,Williamb Bonello ,Chris Smith ,Neogenomics Inc ,Neogenomics Inc View ,Company Pharma Services Division ,Nasdaq ,Company Annual Report On Form ,Clinical Services ,Pharma Services ,Third Quarter Revenue Increased ,Chief Executive ,Adjusted Gross Profit ,Project Catalyst ,Adjusted Net ,Adjusted Gross Profit Margin ,Adjusted Net Loss ,Adjusted Diluted ,Investor Relations ,Pharma Services Division ,Privacy Practices ,Annual Report ,Months Ended September ,Consolidated Balance Sheets ,Gross Profit ,Gross Profit Margin ,Net Loss ,Tests Performed ,Inc View ,Neogenomics ,Reports ,Third ,Quarter ,022 ,Results ,